Last $3.50 HKD
Change Today -0.09 / -2.51%
Volume 916.0K
503 On Other Exchanges
Hong Kong
As of 4:01 AM 07/11/14 All times are local (Market data is delayed by at least 15 minutes).

lansen pharmaceutical holdin (503) Snapshot

Previous Close
Day High
Day Low
52 Week High
03/5/14 - $4.10
52 Week Low
07/17/13 - $2.28
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for LANSEN PHARMACEUTICAL HOLDIN (503)

Related News

No related news articles were found.

lansen pharmaceutical holdin (503) Related Businessweek News

No Related Businessweek News Found

lansen pharmaceutical holdin (503) Details

Lansen Pharmaceutical Holdings Limited, an investment holding company, develops, produces, and sells specialty prescription western pharmaceuticals for the treatment of rheumatic diseases in the People’s Republic of China and internationally. It operates in Specialty Pharmaceuticals, Plant Extract and Healthcare Products, and Other Pharmaceuticals segments. The company’s core rheumatic specialty prescription western pharmaceuticals comprise Pafulin, which includes total glucosides of white peony capsules; Tuoshu, a leflunomide tablet; and MMF. It also offers other pharmaceuticals that include Bazhen Keli, a gynecological product; Yinxingye Pian, Paracetamol orally disintegrating tablets, and Dingpeng Rugao; and Huperzine A capsules, Chanfukang Keli, Ganda Pian, Xinnaojian Jiaonang, Runing Pian, Jian'er Qingjie Ye, and Xiao'er Jianwei Tangjiang, as well as Chinese medicine extracts and healthcare products. In addition, the company distributes human-like collagen dressing products, which are used for the suppression and mitigation of skin inflammation responses caused by various reasons, such as dermatitis, sensitive skin, acne, and laser therapy under the Kefumei brand in China. The company was founded in 2001 and is headquartered in Ningbo, the People’s Republic of China. Lansen Pharmaceutical Holdings Limited is a subsidiary of Cathay International Holdings Limited.

850 Employees
Last Reported Date: 04/14/14
Founded in 2001

lansen pharmaceutical holdin (503) Top Compensated Officers

Chief Executive Officer, Executive Director a...
Total Annual Compensation: $179.0K
Compensation as of Fiscal Year 2013.

lansen pharmaceutical holdin (503) Key Developments

Lansen Pharmaceutical Holdings Limited Approves Final Dividend for the Year Ended December 31, 2013

Lansen Pharmaceutical Holdings Limited approved the recommended final dividend of 6.95 HKD cents per share of USD 0.01 each in the capital of the Company out of the Company's share premium account for the year ended December 31, 2013.

Lansen Pharmaceutical Holdings Co., Ltd Presents at ChinaBio(R) Partnering Forum 2014, May-07-2014

Lansen Pharmaceutical Holdings Co., Ltd Presents at ChinaBio(R) Partnering Forum 2014, May-07-2014 . Venue: Kempinski Hotel Suzhou, Suzhou, China.

Lansen Pharmaceutical Holdings Co. Ltd. Reports Audited Consolidated Cash Flow Results for the Full Year Ended December 31, 2013

Lansen Pharmaceutical Holdings Co. Ltd. reported audited consolidated cash flow results for the year ended December 31, 2013. For the period, the company reported net cash generated from operating activities of USD 4,326,000 compared to USD 6,885,000 a year ago. Purchase of property, plant and equipment was USD 6,355,000 compared to USD 7,767,000 a year ago. Purchase of intangible assets was USD 2,725,000 compared to USD 1,731,000 a year ago. Net debt was USD 33,006,000.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
503:HK $3.50 HKD -0.09

503 Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for 503.
View Industry Companies

Industry Analysis


Industry Average

Valuation 503 Industry Range
Price/Earnings 16.0x
Price/Sales 2.0x
Price/Book 1.7x
Price/Cash Flow 16.0x
TEV/Sales 1.2x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact LANSEN PHARMACEUTICAL HOLDIN, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at